TOYIN KUYORO: Open Payments
NPI 1659788792 · DIAMOND BAR, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,080 in 34 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $0 · 2025 $1,080
Food & beverage: $1,080
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 16 | $442 |
| Amgen Inc. | 4 | $177 |
| Madrigal Pharmaceuticals | 1 | $143 |
| Lilly USA, LLC | 4 | $101 |
| AstraZeneca Pharmaceuticals LP | 2 | $42 |
| ABBVIE INC. | 1 | $34 |
| Exact Sciences Corporation | 1 | $30 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $27 |
| Corcept Therapeutics | 1 | $21 |
Products named: ARISTADA, REZDIFFRA, REPATHA, LYBALVI, MOUNJARO, OTEZLA, FARXIGA, UBRELVY.
Industry payments across CA — which companies pay providers there.
